Published in Toxicol Lett on July 28, 2005
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
A decade of systems biology. Annu Rev Cell Dev Biol (2010) 2.30
A comprehensive functional analysis of tissue specificity of human gene expression. BMC Biol (2008) 2.15
Highly coordinated proteome dynamics during reprogramming of somatic cells to pluripotency. Cell Rep (2012) 1.84
Origin of monocytes and macrophages in a committed progenitor. Nat Immunol (2013) 1.84
Consistency of predictive signature genes and classifiers generated using different microarray platforms. Pharmacogenomics J (2010) 1.69
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood (2006) 1.50
Inflammation-induced endothelial-to-mesenchymal transition: a novel mechanism of intestinal fibrosis. Am J Pathol (2011) 1.45
Selective enrichment of newly synthesized proteins for quantitative secretome analysis. Nat Biotechnol (2012) 1.32
Proteomic characterization of novel alternative splice variant proteins in human epidermal growth factor receptor 2/neu-induced breast cancers. Cancer Res (2010) 1.25
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings. Genome Med (2009) 1.21
Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes. Pharmacogenomics J (2010) 1.16
Bimodal gene expression patterns in breast cancer. BMC Genomics (2010) 1.07
Network analysis of human glaucomatous optic nerve head astrocytes. BMC Med Genomics (2009) 1.03
Proteomics analysis identifies molecular targets related to diabetes mellitus-associated bladder dysfunction. Mol Cell Proteomics (2008) 1.00
Robust extraction of functional signals from gene set analysis using a generalized threshold free scoring function. BMC Bioinformatics (2009) 0.98
Proteomic cornerstones of hematopoietic stem cell differentiation: distinct signatures of multipotent progenitors and myeloid committed cells. Mol Cell Proteomics (2012) 0.96
Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients. Lung Cancer (2013) 0.96
Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Mol Cell Proteomics (2009) 0.94
Rapid temporal dynamics of transcription, protein synthesis, and secretion during macrophage activation. Mol Cell Proteomics (2014) 0.93
Are there any differences between features of proteins expressed in malignant and benign breast cancers? J Res Med Sci (2010) 0.91
Can systems biology understand pathway activation? Gene expression signatures as surrogate markers for understanding the complexity of pathway activation. Curr Genomics (2008) 0.91
Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. BMC Med Genet (2011) 0.90
miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Front Genet (2013) 0.89
Different microRNA profiles in chronic epilepsy versus acute seizure mouse models. J Mol Neurosci (2014) 0.87
Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells. Mol Cell Proteomics (2011) 0.87
The RNA helicase DDX6 regulates cell-fate specification in neural stem cells via miRNAs. Nucleic Acids Res (2015) 0.87
Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression. PLoS One (2012) 0.84
Data mining for gene networks relevant to poor prognosis in lung cancer via backward-chaining rule induction. Cancer Inform (2007) 0.84
Molecular targets for diabetes mellitus-associated erectile dysfunction. Mol Cell Proteomics (2009) 0.83
Constructing endophenotypes of complex diseases using non-negative matrix factorization and adjusted rand index. PLoS One (2012) 0.81
A genome-wide RNAi screen identifies potential drug targets in a C. elegans model of α1-antitrypsin deficiency. Hum Mol Genet (2014) 0.81
A comprehensive look at transcription factor gene expression changes in colorectal adenomas. BMC Cancer (2014) 0.81
Functional analyses of endometriosis-related polymorphisms in the estrogen synthesis and metabolism-related genes. PLoS One (2012) 0.80
A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma. PLoS One (2012) 0.78
Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J Transl Med (2013) 0.78
Microarray labeling extension values: laboratory signatures for Affymetrix GeneChips. Nucleic Acids Res (2009) 0.78
Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models. Neuro Oncol (2013) 0.77
Genetic similarity of chromosome 6 between patients receiving hematopoietic stem cell transplantation and HLA matched sibling donors. Haematologica (2009) 0.77
Transcriptome-wide profiling and posttranscriptional analysis of hematopoietic stem/progenitor cell differentiation toward myeloid commitment. Stem Cell Reports (2014) 0.77
In-silico prediction of drug targets, biological activities, signal pathways and regulating networks of dioscin based on bioinformatics. BMC Complement Altern Med (2015) 0.76
Susceptibility to Childhood Pneumonia: A Genome-Wide Analysis. Am J Respir Cell Mol Biol (2016) 0.75
Treatment of allergic rhinitis with acupoint herbal plaster: an oligonucleotide chip analysis. BMC Complement Altern Med (2016) 0.75
Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer. Oncotarget (2017) 0.75
Challenges of the information age: the impact of false discovery on pathway identification. BMC Res Notes (2012) 0.75
Association between 8q24 rs6983267 polymorphism and cancer susceptibility: a meta-analysis involving 170,737 subjects. Oncotarget (2017) 0.75
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Pathway mapping tools for analysis of high content data. Methods Mol Biol (2007) 4.87
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Cell type-specific DNA methylation patterns in the human breast. Proc Natl Acad Sci U S A (2008) 2.99
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
A comprehensive functional analysis of tissue specificity of human gene expression. BMC Biol (2008) 2.15
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res (2008) 1.82
Atherosclerosis and liver inflammation induced by increased dietary cholesterol intake: a combined transcriptomics and metabolomics analysis. Genome Biol (2007) 1.80
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol (2009) 1.54
Gene expression profiling of human breast tissue samples using SAGE-Seq. Genome Res (2010) 1.41
Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today (2009) 1.40
Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today (2012) 1.39
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform. Methods Mol Biol (2009) 1.31
Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. Mol Pharm (2009) 1.26
Mobile apps for chemistry in the world of drug discovery. Drug Discov Today (2011) 1.26
Methods for predicting human drug metabolism. Adv Clin Chem (2007) 1.24
A quality alert and call for improved curation of public chemistry databases. Drug Discov Today (2011) 1.22
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis (2012) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Epigenetic regulation of cell type-specific expression patterns in the human mammary epithelium. PLoS Genet (2011) 1.15
Biological networks and analysis of experimental data in drug discovery. Drug Discov Today (2005) 1.15
Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Discov Today (2004) 1.14
Reaching out to collaborators: crowdsourcing for pharmaceutical research. Pharm Res (2010) 1.14
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell (2013) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Bacterial peptide recognition and immune activation facilitated by human peptide transporter PEPT2. Am J Respir Cell Mol Biol (2008) 1.13
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12
"Topological significance" analysis of gene expression and proteomic profiles from prostate cancer cells reveals key mechanisms of androgen response. PLoS One (2010) 1.10
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Influence of molecular structure on substrate binding to the human organic cation transporter, hOCT1. Mol Pharmacol (2003) 1.08
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Molecular determinants of ligand selectivity for the human multidrug and toxin extruder proteins MATE1 and MATE2-K. J Pharmacol Exp Ther (2012) 1.07
Bimodal gene expression patterns in breast cancer. BMC Genomics (2010) 1.07
Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today (2013) 1.07
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today (2012) 1.05
Chemical target and pathway toxicity mechanisms defined in primary human cell systems. J Pharmacol Toxicol Methods (2009) 1.04
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Using open source computational tools for predicting human metabolic stability and additional absorption, distribution, metabolism, excretion, and toxicity properties. Drug Metab Dispos (2010) 1.04
Time for cooperation in health economics among the modelling community. Pharmacoeconomics (2010) 1.04
Knowledge-based analysis of proteomics data. BMC Bioinformatics (2012) 1.03
Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01
Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem Res Toxicol (2008) 1.01
A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos (2005) 1.00
Signature pathways identified from gene expression profiles in the human uterine cervix before and after spontaneous term parturition. Am J Obstet Gynecol (2007) 1.00
Structure-activity relationship for FDA approved drugs as inhibitors of the human sodium taurocholate cotransporting polypeptide (NTCP). Mol Pharm (2013) 0.99
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR. Mol Cell Endocrinol (2010) 0.97
Computational prediction of human drug metabolism. Expert Opin Drug Metab Toxicol (2005) 0.97
Parallel worlds of public and commercial bioactive chemistry data. J Med Chem (2014) 0.97
Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev (2002) 0.97
Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci (2005) 0.96
Computational approaches that predict metabolic intermediate complex formation with CYP3A4 (+b5). Drug Metab Dispos (2007) 0.96
Proteins That Underlie Neoplastic Progression of Ulcerative Colitis. Proteomics Clin Appl (2009) 0.96
Redefining Cheminformatics with Intuitive Collaborative Mobile Apps. Mol Inform (2012) 0.96
Comprehensive computational assessment of ADME properties using mapping techniques. Curr Drug Discov Technol (2005) 0.95
Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94
Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis. Pharm Res (2012) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol (2010) 0.93
Discovery of novel antimalarial compounds enabled by QSAR-based virtual screening. J Chem Inf Model (2013) 0.93
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92
Intrinsic disorder in nuclear hormone receptors. J Proteome Res (2008) 0.92
A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab Dispos (2004) 0.92
Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50). J Biomol Screen (2002) 0.91
Integrated network analysis of transcriptomic and proteomic data in psoriasis. BMC Syst Biol (2010) 0.91
Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev (2002) 0.90
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res (2006) 0.90
Reengineering the pharmaceutical industry by crash-testing molecules. Drug Discov Today (2005) 0.90
Quantitative structure activity relationship for inhibition of human organic cation/carnitine transporter. Mol Pharm (2010) 0.90
Computational models for neglected diseases: gaps and opportunities. Pharm Res (2013) 0.89
Troubleshooting computational methods in drug discovery. J Pharmacol Toxicol Methods (2010) 0.89
The evolution of farnesoid X, vitamin D, and pregnane X receptors: insights from the green-spotted pufferfish (Tetraodon nigriviridis) and other non-mammalian species. BMC Biochem (2011) 0.89
Kohonen maps for prediction of binding to human cytochrome P450 3A4. Drug Metab Dispos (2004) 0.88
Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res (2008) 0.88
Putative multifunctional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma (2012) 0.87
A retrospective randomized study of asthma control in the US: results of the CHARIOT study. Curr Med Res Opin (2008) 0.87
Alternative business models for drug discovery. Drug Discov Today (2011) 0.87
The major human pregnane X receptor (PXR) splice variant, PXR.2, exhibits significantly diminished ligand-activated transcriptional regulation. Drug Metab Dispos (2009) 0.87